Liver Cancer
Conditions
Interventions
Experimental group:Transesophageal echocardiography combine isovolemic phlebotomy
Control group:Do not use transesophageal echocardiography combine isovolemic phlebotomy during the surgery
Sponsors
The First Affiliated Hospital of Xi’an Jiaotong University
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: 1. Age = 18 years old, regardless of sex; 2. Laparoscopic hepatectomy under general anesthesia was to be carried out. Preoperative imaging confirmed that the tumor was located in segments ?, ? a, ?, ?, ?, and the expected blood loss was greater than 800ml (preoperative hemoglobin concentration = 11 g/dL in males, = 10 g/dL in females); 3.ASA grade I~III; 4.18kg/m2 = BMI = 30 kg/m2; 5. Patients or their families have a full understanding of the purpose and significance of this trial, voluntarily participate in this clinical trial, and sign an informed consent form.
Exclusion criteria
Exclusion criteria: 1.Active coronary artery disease (except irreversible ischemia within 30 days); 2.Unstable angina pectoris and myocardial infarction within 3 months; 3.Cerebrovascular accidents such as stroke and transient ischemic attack (TIA), etc within 3 months; 4.Severe abnormal liver and renal function (severe liver function abnormality:ALT, AST, ALP, total bilirubin and so on were 2 times higher than the upper limit of normal value. Severe renal dysfunction:creatinine > 2 times the upper limit of normal); 5.Preoperative blood pressure = 160 mmHg (2020 ISH hypertension guidelines = grade 2 hypertension); 6.Abnormal coagulation parameters (INR > 1.5 and / or platelet count < 100000 without warfarin); 7.Prohibit any use of TEE (such as swallowing pain or esophageal stricture); 8.Portal hypertension and esophageal varices with recent bleeding (less than 6 months); 9.Preoperative autologous blood donation; 10.There is active infection; 11.Women who were pregnant or lactating; 12.Those who underwent reoperation within 3 months; 13.Patients who participated in other studies within 30 days.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Allogeneic red blood cell infusion rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Intraoperative blood loss;Boezaart surgical field grading scale;Mean arterial pressure;Phlebotomy volume;Blood transfusion volume;Intraoperative and postoperative complications; | — |
Countries
China
Contacts
Public ContactYing Xiao
The First Affiliated Hospital of Xi’an Jiaotong University
Outcome results
None listed